For example, tyrosine kinase inhibitor (TKI) and mTOR inhibitors are often used in the treatment of ccRCC, but drug resistance is easy to reduce the therapeutic effect. The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.